ROLE AND REGULATION OF PLATELET PROTEIN KINASE C
血小板蛋白激酶 C 的作用和调节
基本信息
- 批准号:3362436
- 负责人:
- 金额:$ 17.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1990
- 资助国家:美国
- 起止时间:1990-07-01 至 1995-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Protein kinase C (PKC) has emerged as a critical enzyme in signal
transduction, cell regulation, cell differentiation, and tumor promotion.
The enzyme is now known to exist as a family of closely-related isoforms
whose individual mechanism and function has not been defined. In human
platelets, PKC has been implicated in a number of platelet functions
including secretion and aggregation as well as negative feedback mechanisms
(on platelet activation). We have identified four isoenzymes of PKC in
platelets. The long-term goals are to define the role of PKC in platelet
function. This proposal aims at studying the hypothesis that different PKC
isoenzymes are differentially regulated to transduce selective functions.
Our laboratory, which has extensive experience in the biochemical
characterization of PKC and in the study of platelet biology, is uniquely
suited to evaluate these questions. The specific aims of this proposal are,
therefore, directed at determining the mechanism and significance of PKC
isoenzymes from platelets. These will be addressed by: 1) purifying PKC
isoenzymes from platelets (using FPLC) and studying their in vitro
regulation (using mixed micellar methodologies that we have developed); 2)
determining the intracellular localization of PKC isoenzymes in resting and
activated platelets, respectively, (by monitoring enzyme activity, phorbol
binding and by Western blots) and; 3) studying the in situ (physiologic)
regulation of platelet PKC isoenzymes and determining their selective
substrate phosphorylations (using an in vitro model that we have
developed). These studies will provide the necessary biochemical background
for determining the mechanism and physiologic regulation of PKC isoenzymes.
Such knowledge is of great significance for improving our understanding of
the role of platelets in hemostasis and in the pathophysiology of
arteriovascular disease. This improved biochemical knowledge may lead to
more efficacious and rational antiplatelet drug development. Knowledge
gained from the platelet model should prove to be of great usefulness for
investigators studying the regulation and role of PKC isoenzymes in various
other cell systems.
蛋白激酶C(PKC)是一种重要的信号转导酶,
转导、细胞调节、细胞分化和肿瘤促进。
现在已知这种酶是作为一个密切相关的同种型家族存在的
其单独的机制和功能尚未确定。人
在血小板中,PKC与许多血小板功能有关
包括分泌和聚集以及负反馈机制
(on血小板活化)。我们已经确定了四种PKC同工酶,
血小板长期目标是明确PKC在血小板活化中的作用,
功能该建议旨在研究不同的PKC
同工酶被不同地调节以实现选择性功能。
我们的实验室在生物化学方面有着丰富的经验,
PKC的特性和血小板生物学的研究,是唯一的
适合评估这些问题。这项建议的具体目标是,
因此,旨在明确PKC的作用机制和意义,
血小板的同工酶。这些将通过以下方法解决:1)纯化PKC
血小板同工酶(FPLC)及其体外研究
调节(使用我们开发的混合胶束方法); 2)
确定静息和静息状态下PKC同工酶的细胞内定位,
活化血小板,分别(通过监测酶活性,佛波醇
结合和蛋白质印迹)和; 3)研究原位(生理)
血小板PKC同工酶的调节及其选择性
底物磷酸化(使用我们已经建立的体外模型,
发达)。这些研究将提供必要的生物化学背景
用于确定PKC同工酶的机制和生理调节。
这些知识对于提高我们对
血小板在止血中的作用以及在
动脉血管疾病这种生物化学知识的提高可能会导致
更有效、更合理的抗血小板药物开发。知识
从血小板模型中获得的信息应该被证明是非常有用的
研究PKC同工酶在各种疾病中的调节和作用的研究人员,
其他细胞系统。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YUSUF AWNI HANNUN其他文献
YUSUF AWNI HANNUN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YUSUF AWNI HANNUN', 18)}}的其他基金
Protein kinase C in Lung Cancer with mutant EGFR
EGFR 突变肺癌中的蛋白激酶 C
- 批准号:
10618917 - 财政年份:2020
- 资助金额:
$ 17.36万 - 项目类别:
Protein kinase C in Lung Cancer with mutant EGFR
EGFR 突变肺癌中的蛋白激酶 C
- 批准号:
10454776 - 财政年份:2020
- 资助金额:
$ 17.36万 - 项目类别:
Protein kinase C in Lung Cancer with mutant EGFR
EGFR 突变肺癌中的蛋白激酶 C
- 批准号:
9888660 - 财政年份:2020
- 资助金额:
$ 17.36万 - 项目类别:
Neutral Sphingomyelinases and Bioactive Ceramides
中性鞘磷脂酶和生物活性神经酰胺
- 批准号:
10437811 - 财政年份:2016
- 资助金额:
$ 17.36万 - 项目类别:
Neutral Sphingomyelinases and Bioactive Ceramides
中性鞘磷脂酶和生物活性神经酰胺
- 批准号:
10640899 - 财政年份:2016
- 资助金额:
$ 17.36万 - 项目类别:
Neutral sphingomyelinases and bioactive ceramides
中性鞘磷脂酶和生物活性神经酰胺
- 批准号:
9071506 - 财政年份:2016
- 资助金额:
$ 17.36万 - 项目类别:
Diversity Supplement for Bernandie Jean: Neutral sphingomyelinases and bioactive ceramides
Bernandie Jean 的多样性补充:中性鞘磷脂酶和生物活性神经酰胺
- 批准号:
9752140 - 财政年份:2016
- 资助金额:
$ 17.36万 - 项目类别: